US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,382.59

+5.930.43%

Number of Gainers:3

Number of Losers:- -

Number of Flat:- -

PE:- -

High:1,396.81

Open:1,376.83

Low:1,376.83

Close:1,376.66

Loading ...

Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now

Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?

Bank of America Securities Remains a Buy on Gilead Sciences (GILD)

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

Simply Wall St.

Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115

THOMSON REUTERS

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Gilead Sciences sets aside $200 million to resolve HIV drug probe

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1382.588,"timestamp":1741208399999,"preClose":1376.6566,"halted":0,"volume":18213174,"delay":0,"changeRate":0.004309,"change":5.931396,"pbRate":5.765336,"amount":2063456275.663362,"amplitude":0.014515,"prevYearClose":1164.883,"fiveDayClose":1330.3182,"twentyDayClose":1252.4534,"turnoverRate":0.005809,"marketCap":364774630820,"floatMarketCap":354170504940,"peRate":30.124118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1396.8141,"amplitude":0.014515,"preClose":1376.6566,"low":1376.8324,"pbRate":"5.760232","latestPrice":1382.588,"volume":18213174,"delay":0,"open":1376.8324,"prevYearClose":1164.883,"prevWeekClose":1356.2184,"prevMonthClose":1356.2184,"prevQuarterClose":1164.883,"fiveDayClose":1330.3182,"twentyDayClose":1252.4534,"sixtyDayClose":1190.7347,"secType":"PLATE","market":"US","turnoverRate":0.005809,"peRate":30.09745,"marketCap":364774630820,"floatMarketCap":354170504940,"timestamp":1741208399999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":3,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517096929","title":"Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2517096929","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517096929?lang=en_us&edition=fundamental","pubTime":"2025-03-06 04:43","pubTimestamp":1741207388,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look at where Novartis AG  stands against the other undervalued stocks.While talking about how the Fed might react to the tariffs, Fisher mentioned that it is a little too early to guess. The Fed is bringing inflation down and we are getting closer to the 2% target, however, at the same time tariff increases the cost of doing business, which might slow down the economy and tickle up inflation. To conclude Fisher noted that tariffs won’t be digested quickly and will take time.For this article, we used the Finviz stock screener, Yahoo Finance, and Seeking Alpha. Using the screener we aggregated a list of stocks trading below the forward P/E of 15 and earnings growth expectations this year. Next, we cross-checked the Forward P/E from Seeking Alpha and Earnings growth from Yahoo Finance. Lastly, after sorting our list by market capitalization, we ranked the stock","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-ag-nvs-among-best-204308512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","US30Y.BOND","IE00B4R5TH58.HKD","IE0009355771.USD","BK4210","US5Y.BOND","BK4585","US10Y.BOND","US12M.BOND","US7Y.BOND","IE00BJT1NW94.SGD","US3Y.BOND","US2Y.BOND","AG","IE00BFTCPJ56.SGD","BK4532","NVS","IE00B2B36J28.USD","US6M.BOND","LU0211331839.USD","BK4578","IE0002141913.USD","BK4007","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2517949629","title":"Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517949629","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517949629?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:15","pubTimestamp":1741184103,"startTime":"0","endTime":"0","summary":"Have you been paying attention to shares of Gilead Sciences ?Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the year compared to the 6% move for the Zacks Medical sector and the 6% return for the Zacks Medical - Biomedical and Genetics industry.The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on February 11, 2025, Gilead reported EPS of $1.9 versus consensus estimate of $1.67.For the current fiscal year, Gilead is expected to post earnings of $7.86 per share on $28.55 billion in revenues. This represents a 70.13% change in EPS on a -0.7% change in revenues. For the next fiscal year, the company is expected to earn $8.17 per share on $29.7 billion in revenues. This represents a year-over-year change of 3.9% and 4.01%,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-hits-141503605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKVL7J92.USD","LU0289739699.SGD","LU1066053197.SGD","LU1430594728.SGD","LU1571399168.USD","IE00B3T34201.USD","BK4139","LU2087621335.USD","IE00BN0W2W23.USD","IE00B19Z3B42.SGD","BK4533","LU1066051498.USD","LU1839511570.USD","BK4007","IE00BZ1G4Q59.USD","LU0823416689.USD","IE0002270589.USD","BK4585","LU0234570918.USD","IE00BN0W2T93.GBP","LU0058720904.USD","BK4588","BK4568","BK4578","IE00BN0W2V16.EUR","LU1585245621.USD","JAZZ","LU2468319806.SGD","LU0889565916.HKD","LU0320765992.SGD","BK4550","IE00B19Z3581.USD","BK4532","BK4566","BK4583","LU2089984988.USD","IE00B7SZLL34.SGD","GILD","IE00BSNM7G36.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2517991313","title":"Bank of America Securities Remains a Buy on Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517991313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517991313?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:57","pubTimestamp":1741175855,"startTime":"0","endTime":"0","summary":"In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089984988.USD","LU0170899867.USD","LU0130102774.USD","GILD","LU0130103400.USD","LU0971096721.USD","LU1496350171.SGD","LU0417517546.SGD","IE00BBT3K403.USD","LU0208291251.USD","BK4550","LU0256863902.USD","LU1280957306.USD","LU1668664300.SGD","LU0098860793.USD","LU0648000940.SGD","LU1880398554.USD","LU1571399168.USD","BK4578","BAC","LU1883839398.USD","LU2133065610.SGD","LU0053666078.USD","BK4207","LU0109394709.USD","LU0320765992.SGD","LU1066051498.USD","BK4532","BK4139","BK4585","LU2087621335.USD","LU0058720904.USD","BK4588","LU2129689605.HKD","LU1363072403.SGD","IE00BLSP4452.SGD","LU0256863811.USD","BK4568","LU1201861165.SGD","LU0289739699.SGD","BK4583","LU1894683264.USD","LU1880398471.USD","LU1162221912.USD","BK4504","LU1791807156.HKD","IE00BLSP4239.USD","IE00BKVL7J92.USD","LU2129689431.USD","LU1201861249.SGD"],"gpt_icon":0},{"id":"2517924507","title":"Novartis Earns Near-Best Overall Rating As Profit Growth Climbs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517924507","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517924507?lang=en_us&edition=fundamental","pubTime":"2025-03-05 16:00","pubTimestamp":1741161600,"startTime":"0","endTime":"0","summary":"On Wednesday,  Novartis ADR got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novartis-adr-receives-composite-rating-upgrade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00BN0W2W23.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4007","IE00B4R5TH58.HKD","BK4588","IE00BN0W2V16.EUR","NVS","IE00B2B36J28.USD","IE00BN0W2T93.GBP","JAZZ","BK4578","LU0889565916.HKD","LU0109394709.USD","BK4585","BK4532","LU0823416689.USD","PAHC","IE0002141913.USD","BK4533","LU0320765992.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"2517398310","title":"Pharmaceutical Stocks Hit New Highs Amid Market Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2517398310","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517398310?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:34","pubTimestamp":1741109640,"startTime":"0","endTime":"0","summary":"The stock market has a way of proving the masses wrong.After all the chatter about the new administration’s potentially adverse impact on pharmaceutical stocks and related industries, the broader health care sector is leading the charge in 2025.Following the latest market volatility, the S&P 500 is now in negative territory on the year. It’s somewhat surprising to peak behind the curtain and see that 9 of 11 S&P sectors remain green.The price action in the stock market has been fast and furious as investors repositioned their portfolios for the new year. Sector rotation has been on full display, with institutions foregoing growth and technology positions and shifting to more defensive areas like staples, health care and utilities.Historical research studies suggest that approximately half of a stock’s price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharmaceutical-stocks-hit-highs-amid-173400932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1571399168.USD","BK4585","LU2468319806.SGD","LU0320765992.SGD","LU1430594728.SGD","BK4583","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1066053197.SGD","LU0234570918.USD","BK4566","IE00BZ1G4Q59.USD","GILD","BK4568","IE00B19Z3581.USD","BK4550","LU0058720904.USD","BK4588","IE00B7SZLL34.SGD","BK4532","IE00BSNM7G36.USD","LU1585245621.USD","LU2089984988.USD","BK4578","IE0002270589.USD","LU1066051498.USD","LU2087621335.USD","LU0889565916.HKD","LU0109394709.USD","BK4139","LU1839511570.USD","IE00B3T34201.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2517817604","title":"Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517817604","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517817604?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:08","pubTimestamp":1741108082,"startTime":"0","endTime":"0","summary":"As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly assessing opportunities that may arise from these turbulent conditions. In such an environment, identifying stocks that appear to be undervalued based on intrinsic estimates can provide potential avenues for investment, as they might offer resilience against broader economic challenges.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Gilead Sciences shows potential as an undervalued stock based on cash flows, trading at US$115.99, significantly below its estimated fair value of US$228.07. Despite high debt levels and a current profit margin dip to 1.7%, earnings are forecasted to grow significantly by 23.6% annually over the next three years, outpacing the broader U.S. market's growth expectations of 14%. Recent regulatory advancements for key products like lenacapavir may bolster future cash flows.Overview: Intuit Inc. offers financial management, co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-gilead-sciences-2-more-170802498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0256863811.USD","LU1430594728.SGD","LU2237438978.USD","LLY","IE00BFTCPJ56.SGD","LU1988902786.USD","LU0128526141.USD","BK4139","LU1585245621.USD","LU1791807156.HKD","IE00BZ1G4Q59.USD","BK4516","LU1291159041.SGD","LU0823416689.USD","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","LU2237443549.SGD","IE00B4R5TH58.HKD","BK4533","BK4568","LU0672654240.SGD","LU1814569148.SGD","LU0820561818.USD","WK","LU0466842654.USD","SG9999018865.SGD","BK4581","SSB","JBTM","LU1839511570.USD","LU2237443465.HKD","LU2087621335.USD","LU0471298694.HKD","BC","LU1093756168.USD","LU1280957306.USD","LU2237443895.HKD","LU1127390331.HKD","SMWB","GB00BDT5M118.USD","LU0114720955.EUR","BK4578","GILD","SGXZ99366536.SGD","INTU","LU2324357040.USD","LU0079474960.USD","DFS","LU1868837136.USD","LU0689472784.USD","SG9999014898.SGD"],"gpt_icon":1},{"id":"2516676930","title":"Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676930?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:15","pubTimestamp":1741094114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nAZN3HPGL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4139","BK4550","BK4578","LU0109394709.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","IE0002270589.USD","LU1571399168.USD","GILD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BZ1G4Q59.USD","LU1066051498.USD","LU0058720904.USD","BK4566","LU1066053197.SGD","LU2089984988.USD","IE00BKVL7J92.USD","IE00B19Z3581.USD","LU1430594728.SGD","BK4583","LU0234570918.USD","LU1585245621.USD","BK4568","IE00B3T34201.USD","BK4585","BK4588","LU1839511570.USD","LU2468319806.SGD","LU2087621335.USD","BK4532"],"gpt_icon":0},{"id":"2517600123","title":"Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600123","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517600123?lang=en_us&edition=fundamental","pubTime":"2025-03-04 16:00","pubTimestamp":1741075200,"startTime":"0","endTime":"0","summary":"A Relative Strength Rating upgrade for Novartis shows improving technical performance. Will it continue?","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2019/01/Stock-DrugsResearch-09-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2019/01/Stock-DrugsResearch-09-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novartis-adr-trying-to-close-in-on-key-technical-benchmark-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4007","IE0002141913.USD","IE00BJT1NW94.SGD","RS","IE00B4R5TH58.HKD","PAHC","IE00BJJMRZ35.SGD","BK4532","BK4585","IE00B2B36J28.USD","BK4578","BK4588","NVS","BK4006","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"2516958616","title":"Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516958616","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516958616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:50","pubTimestamp":1741042206,"startTime":"0","endTime":"0","summary":"In the latest market close, Gilead Sciences  reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow experienced a drop of 1.48%, and the technology-dominated Nasdaq saw a decrease of 2.64%.The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% over the last month, surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26%.The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share  are projected to be $1.73, reflecting a 231.06% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.78 billion, indicating a 1.36% growth compared to the corresponding quarter of the prior year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-rises-market-225006380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","BK4588","BK4578","LU0109394709.USD","LU1839511570.USD","LU0234570918.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU2468319806.SGD","BK4583","LU2089984988.USD","GILD","BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","LU1066053197.SGD","LU0320765992.SGD","LU2087621335.USD","IE00B19Z3581.USD","IE00B3T34201.USD","BK4532","BK4568","LU1585245621.USD","LU0889565916.HKD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4585","LU1571399168.USD","BK4139","IE00BKVL7J92.USD","LU1066051498.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2516653634","title":"Gilead Sciences sets aside $200 million to resolve HIV drug probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653634","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653634?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:18","pubTimestamp":1741018712,"startTime":"0","endTime":"0","summary":"Gilead Sciences sets aside $200 million to resolve HIV drug probeBy Luc Cohen NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL2N3PM0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0889565916.HKD","LU1066051498.USD","BK4578","IE00BKVL7J92.USD","IE00B3T34201.USD","BK4550","IE00B19Z3581.USD","BK4585","BK4583","LU2468319806.SGD","GILD","BK4532","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0320765992.SGD","LU1839511570.USD","LU0234570918.USD","LU0058720904.USD","LU1430594728.SGD","BK4566","IE00BZ1G4Q59.USD","LU1571399168.USD","LU2087621335.USD","IE00B7SZLL34.SGD","BK4588","IE00BSNM7G36.USD","BK4139","LU0109394709.USD","LU1066053197.SGD","LU1585245621.USD","IE0002270589.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2516656745","title":"KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656745","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656745?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:59","pubTimestamp":1741017540,"startTime":"0","endTime":"0","summary":"Krystal BiotechKRYS announced that the European Medicines Agency'sCommittee for Medicinal Products for Human Use  has adopted a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa . The intended DEB patient population includes those who have mutations in the COL7A1 gene starting from birth.DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. Vyjuvekis a non-invasive, topical, redosable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds.In the past three months, shares of Krystal Biotech have plunged 18.3% compared with the industry’s 0.6% decline.More on CHMP’s Positive Opinion on Vyjuvek’s EU Approval. The positive CHMP opinion recommending the approval of Vyjuvekfor the DEB indication in the EU is based on the results of Krystal Biotech’s phase I/II GEM-1 and phase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-gets-positive-chmp-opinion-155900015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2065171311.SGD","IE00BSNM7G36.USD","BMRN","LU1839511570.USD","LU2089984988.USD","BK4532","LU2087621335.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU2065171402.SGD","BK4583","LU0889565916.HKD","IE00BZ1G4Q59.USD","BK4566","BK4588","GILD","IE00BKVL7J92.USD","BK4585","LU1585245621.USD","LU2065170008.USD","LU2065169927.USD","CHMP","KRYS","LU0234570918.USD","LU1571399168.USD","LU1066051498.USD","BK4568","LU0289739699.SGD","BK4578","LU0320765992.SGD","FOLD","IE0002270589.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU0058720904.USD","BK4156","LU0109394709.USD","IE00B3T34201.USD","BK4087","BK4550","IE00B19Z3B42.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2516653171","title":"Novartis Gets CHMP Opinion for Label Expansion of Fabhalta","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653171","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653171?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:39","pubTimestamp":1741012740,"startTime":"0","endTime":"0","summary":"Novartis NVS announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway 6-7.The CHMP recommended granting a marketing authorization to Fabhalta for the treatment of adults with C3 glomerulopathy , an ultra-rare, progressive kidney disease with no currently approved treatments.A final decision from the European Commission  is expected in two months.The CHMP’s positive opinion is based on robust data from APPEAR-C3G, a randomized placebo-controlled phase III study. The study showed patients treated with Fabhalta, in addition to supportive care, achieved a statistically significant and clinically meaningful 35.1% reduction in proteinuria  at 6 months when compared to placebo.A potential approval will make Fabhalta the only drug indicated to target the underlying cause of C3G.Shares of Novartis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-gets-chmp-opinion-label-143900090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJT1NW94.SGD","BK4139","LU1839511570.USD","LU2089984988.USD","LU0058720904.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","BK4578","BK4583","IE00B4R5TH58.HKD","LU2468319806.SGD","CHMP","BK4568","LU1066053197.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","IE00B19Z3581.USD","BK4550","IE00BSNM7G36.USD","IE00B3T34201.USD","LU2087621335.USD","EC","BMRN","IE0002270589.USD","BK4588","IE00B7SZLL34.SGD","NVS","LU0234570918.USD","IE00BZ1G4Q59.USD","BK4532","BK4007","IE00B2B36J28.USD","BK4201","LU0320765992.SGD","LU1066051498.USD","LU0289739699.SGD","LU0109394709.USD","IE0002141913.USD","LU1585245621.USD","GILD","IE0009355771.USD","LU0211331839.USD","BK4087","LU1571399168.USD","BK4585","BK4566"],"gpt_icon":0},{"id":"2516150651","title":"U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2516150651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516150651?lang=en_us&edition=fundamental","pubTime":"2025-03-03 15:43","pubTimestamp":1740987813,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund March 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM0FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTLS","LU0054578231.USD","BJ","GEV","IE00BZ9MQY76.HKD","BLD","UHS","IE00B66KJ199.SGD","LU1066051498.USD","DCBO","BK4568","PRAX","LU0345774631.USD","LU0289739699.SGD","FSS","BK4088","BK4578","GILD","IE00B2PGVK34.USD","LU0724618433.USD","LU2065731478.USD","LU1721428933.USD","CABO","LU2087621335.USD","FDX","BK4131","IE00B19Z9Z06.USD","LU1978683503.SGD","LU0323240290.USD","IE00BN0W2W23.USD","PUBM","IE00B3T34201.USD","LU2265009873.SGD","LU2326559502.SGD","LU2125910336.SGD","MSDL","ASTH","LU0889565916.HKD","WTS","LU2298064838.USD","BK4096","BK4185","LU0251142724.SGD","LU1992135399.USD","HUBB","ADSK","ARDT","FOXF","VTR"],"gpt_icon":1},{"id":"2516556797","title":"Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2516556797","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516556797?lang=en_us&edition=fundamental","pubTime":"2025-03-01 20:53","pubTimestamp":1740833610,"startTime":"0","endTime":"0","summary":"The board of Gilead Sciences, Inc.  has announced that it will be paying its dividend of $0.79 on the 28th of March, an increased payment from last year's comparable dividend. This takes the annual payment to 2.8% of the current stock price, which is about average for the industry.Gilead Sciences' Future Dividend Projections Appear Well Covered By Earnings. We aren't too impressed by dividend yields unless they can be sustained over time. Prior to this announcement, the company was paying out 800% of what it was earning, however the dividend was quite comfortably covered by free cash flows at a cash payout ratio of only 38%. Generally, we think cash is more important than accounting measures of profit, so with the cash flows easily covering the dividend, we don't think there is much reason to worry.Analysts expect a massive rise in earnings per share in the next year. Assuming the dividend continues along recent trends, we estimate that the payout ratio could reach 47%, which is in a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaq-gild-increasing-125330339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","IE00B7SZLL34.SGD","BK4566","MNQmain","BK4112","IE00BKPKM429.USD","LU1066053197.SGD","NVIW.SI","IE00BZ1G4Q59.USD","PSQ","LU1839511570.USD","LU0289739699.SGD","LU2210150020.SGD","GILD","LU0234570918.USD","QID","LU2087621335.USD",".IXIC","BK4585","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","BK4568","BK4583","LU2468319806.SGD","NQmain","IE00B64PRP62.GBP","LU1585245621.USD","LU0058720904.USD","USAW.SI","TSYW.SI","LU1066051498.USD","LU0109394709.USD","LU2095319765.USD","LU0320765992.SGD","BK4588","IE00BSNM7G36.USD","BK4532","LU2210149790.SGD","USJW.SI","LU1571399168.USD","IE0002270589.USD","IE00B19Z3B42.SGD","TQQQ","IE00B3T34201.USD","LU0889565916.HKD","QLD","BK4139","SQQQ"],"gpt_icon":1},{"id":"2516130552","title":"Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516130552","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516130552?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:12","pubTimestamp":1740766320,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY.Shares of KYMR have lost 30.1% year to date compared with the industry’s decline of 8%.In October, Kymera initiated the phase I study on KT-621 in healthy volunteers. KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6.Kymera intends to advance KT-295, an investigational, first-in-class, once daily, oral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymeras-q4-loss-wider-expected-181200761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","BK4588","IE00BFXG1179.USD","LU1066051498.USD","BK4568","LU1839511570.USD","LU0289739699.SGD","BK4578","GILD","BK4583","LU2087621335.USD","LU2468319806.SGD","IE0002270589.USD","BK4007","IE00BZ1G4Q59.USD","LU1430594728.SGD","BK4139","LU1066053197.SGD","LU1585245621.USD","IE00B7SZLL34.SGD","BMRN","IE00B3T34201.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU0889565916.HKD","LU1571399168.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4566","SNY","KYMR","BK4532","BK4585","LU0109394709.USD","BK4550"],"gpt_icon":0},{"id":"2516379060","title":"Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379060?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:36","pubTimestamp":1740753360,"startTime":"0","endTime":"0","summary":"Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.XENE, in collaboration with Neurocrine, is also currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, as a potential treatment for certain types of epilepsy. In the earnings releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q4-loss-narrower-expected-143600608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065170008.USD","LU2089984988.USD","BK4588","LU1066051498.USD","BK4568","LU1839511570.USD","ABVC","LU0289739699.SGD","BK4578","GILD","BK4583","LU2087621335.USD","LU2468319806.SGD","IE0002270589.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","BK4139","LU1066053197.SGD","LU2065171311.SGD","LU1585245621.USD","IE00B7SZLL34.SGD","LU2065169927.USD","BMRN","IE00B3T34201.USD","LU2324357040.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU0889565916.HKD","LU1571399168.USD","LU2065171402.SGD","XENE","NBIX","LU0058720904.USD","IE00B19Z3581.USD","BK4566","BK4532","BK4585","LU0109394709.USD","BK4550"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":57}]}}